Alniditan is a selective 5-HT_1B/1D receptor agonist used primarily in pharmacological research for the treatment of acute migraine attacks. It targets specific serotonin receptors in the brain, leading to vasoconstriction and reduction of neurogenic inflammation, thereby alleviating symptoms such as severe headache, nausea, photophobia, and phonophobia. This compound is particularly studied for its potential in patients refractory to other antimigraine therapies. As a research chemical with 98% purity, its handling requires appropriate laboratory safety protocols due to potential pharmacological effects and limited clinical data.